PCSK6 is upregulated in pancreatic cancer liver metastases, and its inactivation results in the decreased migratory potential of tumour cells in pancreatic cancer and reprogramming of cell‒cell junctions (He et al., 2022). Here, PCSK6 is linked to pancreatic neoplasm.